Improving prostate cancer treatment with enzalutamide
Developing therapies to improve enzalutamide in CRPC
This study is looking for ways to make enzalutamide, a treatment for metastatic prostate cancer, work better by understanding how certain proteins help cancer cells survive, so we can find new ways to help patients get better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11056069 on NIH RePORTER |
What this research studies
This research aims to enhance the effectiveness of enzalutamide, a treatment for metastatic prostate cancer that has shown promise but often leads to resistance in patients. By investigating the role of glutamic pyruvate transaminases (GPT) in cancer cell survival, the study seeks to identify new therapeutic strategies that can improve patient outcomes. The researchers will utilize advanced techniques, including CRISPR/Cas9 screening, to explore how GPT contributes to resistance against enzalutamide and to test potential inhibitors that could enhance treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have experienced limited success with current enzalutamide treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not been treated with enzalutamide may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for men with castration-resistant prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Qian, Zheng David — Oregon Health & Science University
- Study coordinator: Qian, Zheng David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.